GlassScriptPhysician profile
Jayanta Choudhury
NPI 1851312268
$5,465.70
in general payments reported to CMS, 2019-2025
33 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $579 · 2021: $1,023 · 2022: $382 · 2023: $486 · 2024: $955 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,524.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,508.99 | 2019-2025 | Linzess, Creon, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $781.93 | 2019-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $617.36 | 2019-2025 | Axios, Autotome Rx 49, X-Tack Endoscopic Helix Tacking System |
| Nestle Healthcare Nutrition INC. | $318.02 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $293.31 | 2024-2025 | Vowst, Zenpep |
| Cook Medical LLC | $217.31 | 2019-2025 | Fusion, Echotip Insight, Evolution |
| Takeda Pharmaceuticals U.S.A., INC. | $208.97 | 2019-2023 | Entyvio |
| Janssen Biotech, INC. | $178.39 | 2019-2024 | Stelara |
| Ironwood Pharmaceuticals, INC | $177.96 | 2020-2024 | Linzess |
| Shionogi INC | $132.17 | 2019-2020 | |
| Madrigal Pharmaceuticals | $108.62 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $104.91 | 2021-2024 | Zeposia |
| Pfizer INC. | $97.62 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $68.97 | 2024-2025 | Voquezna |
| Vivus LLC | $67.11 | 2023-2025 | Pancreaze |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $59.35 | 2020-2021 | |
| Ardelyx, INC. | $57.68 | 2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $53.68 | 2019-2020 | |
| Ambu INC. | $52.77 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $48.52 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $46.79 | 2019-2021 | |
| Echosens North America, INC. | $44.08 | 2024-2025 | Fibroscan, Fibroscan |
| Daiichi Sankyo INC. | $37.36 | 2019 | |
| Allergan, INC. | $35.12 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.39 | 2023 | Dupixent |
| Capsovision, INC. | $20.60 | 2024 | Capsocam Plus |
| Micro-Tech Endoscopy USA, INC. | $19.80 | 2024 | Eyemax |
| Genzyme Corporation | $18.81 | 2023 | |
| Redhill Biopharma INC. | $18.06 | 2021 | |
| Novo Nordisk INC | $14.44 | 2025 | Wegovy |
| Ethicon US, LLC | $12.30 | 2021 | |
| Covidien LP | $12.10 | 2019 | |
| Shire North American Group INC | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayanta Choudhury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.